Peregrine Ventures

Peregrine Ventures is an Israeli venture capital firm dedicated to advancing medical innovation through strategic investments in early-stage technology companies, with a strong emphasis on life sciences and healthcare sectors. The firm focuses on supporting and advancing medical innovation through global strategic investments, bringing together deep industry knowledge and an embedded synergetic strategy to assist portfolio companies in developing meaningful breakthroughs in healthcare. Peregrine Ventures is Israel's first dedicated healthcare fund, committed to improving patients' quality of life by investing in and supporting life-changing healthcare opportunities. With decades of experience, the team is dedicated to supporting portfolio companies and providing them with valuable knowledge to build winning business strategies, create successful strategic alliances, recruit strong teams, and bring healthcare innovations to life. Peregrine Ventures has been recognized as Israel's most active healthtech investor, making 15 strategic investments in the health technology sector in 2024 alone. These investments align with the firm's core mission of improving patient outcomes through innovation, addressing some of healthcare's most pressing challenges. The firm's investment strategy centers on three primary pillars: brain (injuries and diseases), cardiovascular, and oncology. Peregrine builds clusters of complementary technologies, addressing each field through diverse approaches such as pharmaceuticals, therapeutic medical devices, digital health, and robotics. The firm collaborates with innovators in Israel's health tech ecosystem, a global hub for medical breakthroughs, reaffirming its dedication to identifying and nurturing cutting-edge companies that address critical unmet needs in healthcare. Peregrine Ventures' robust portfolio includes fast-growing companies, many of them with valuations of hundreds of millions of dollars in the fields of pharma-oncology, medical devices, implants, and digital health. The firm has achieved significant exits, including a $300 million exit from Cardiovalve, a pioneering transcatheter mitral and tricuspid valve replacement company, bringing total proceeds to $1 billion. Additionally, Peregrine realized a $500 million exit from CartiHeal following FDA approval of an implant for the treatment of cartilage and osteochondral defects. These successful exits highlight the firm's commitment to supporting innovative healthcare companies and bringing groundbreaking medical technologies to market. Peregrine Ventures' dedicated investment vehicles include early and mid-stage funds, the 'Incentive' Incubator, and Peregrine Growth, a fund dedicated to more mature companies in their last rounds of financing prior to an M&A or IPO. The firm's commitment to identifying, funding, and partnering with entrepreneurs continues to yield outstanding results, shaping the future of healthcare through strategic investments and support for innovative companies.